Everything below concerns peptide purity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-25. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Non-diabetics' beta cells routinely and automatically manage this by continual glucose level monitoring and insulin release. All such decisions by a diabetic must be based on experience and training (i.e., at the direction of a physician, PA, or in some places a specialist diabetic educator) and, further, specifically based on the individual experience of the person. But it is not straightforward and should never be done by habit or routine. With some care however, it can be done reasonably well in clinical practice. For example, some people with diabetes require more insulin after drinking skim milk than they do after taking an equivalent amount of fat, protein, carbohydrate, and fluid in some other form. Their particular reaction to skimmed milk is different from other people with diabetes, but the same amount of whole milk is likely to cause a still different reaction even in that person. Whole milk contains considerable fat while skimmed milk has much less. It is a continual balancing act for all people with diabetes, especially for those taking insulin. People with insulin-dependent diabetes typically require some base level of insulin (basal insulin), as well as short-acting insulin to cover meals (bolus also known as mealtime or prandial insulin). Maintaining the basal rate and the bolus rate is a continuous balancing act that people with insulin-dependent diabetes must manage each day.
== Pharmacology == DL-threo-beta-benzyloxyaspartate (TBOA) is an inhibitor of the excitatory amino acid transporters. Selective inhibitors for EAAT1 have recently been discovered based on 25 combinations of substitutions at the 4 and 7 positions of 2-amino-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitril.
== References == Atkins, P.W.; De Paula, J. (2006). Physical Chemistry (8th. ed.). Oxford University Press. ISBN 0-19-870072-5. Denbeigh, K. (1981). The principles of chemical equilibrium (4th. ed.). Cambridge, U.K.: Cambridge University Press. ISBN 0-521-28150-4. A classic book, last reprinted in 1997. Mendham, J.; Denney, R. C.; Barnes, J. D.; Thomas, M. J. K. (2000), Vogel's Quantitative Chemical Analysis (6th ed.), New York: Prentice Hall, ISBN 0-582-22628-7
=== Cardiovascular disease === Vitamin D supplementation is not associated with a reduced risk of stroke, cerebrovascular disease, myocardial infarction, or ischemic heart disease. Supplementation does not lower blood pressure in the general population. One meta-analysis found a small increase in risk of stroke when calcium and vitamin D supplements were taken together.
Sources: en.wikipedia.org
== Production == ANP is synthesized as an inactive preprohormone, encoded by the human NPPA gene located on the short arm of chromosome 1. The NPPA gene is expressed primarily in atrial myocytes and consists of 2 introns and three exons, with translation of this gene yielding a high molecular mass 151 amino acid polypeptide known as preproANP. The preprohormone is activated via post-translational modification that involves cleavage of the 25 amino acid signal sequence to produce proANP (26–151), a 126 amino acid peptide that is the major form of ANP stored in intracellular granules of the atria. Following stimulation of atrial cells, proANP is released and rapidly converted to the 28-amino-acid C-terminal mature ANP (124–151) on the cell surface by the cardiac transmembrane serine protease corin; the remaining N-terminal part is called "NT-proANP" (26–123). ANP is secreted in response to:
Dystrophic epidermolysis bullosa (DEB) is an inherited variant affecting the skin and other organs. DEB is caused by genetic defects (or mutations) within the human COL7A1 gene encoding the protein type VII collagen (collagen VII). DEB-causing mutations can be either autosomal dominant or autosomal recessive. Epidermolysis bullosa pruriginosa and albopapuloid epidermolysis bullosa (Pasini disease) are rare subtypes of this disease.
== Book chapters == 1. Richoz O, Hafezi F Modifications for Thin Corneas, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 51–55. 2. Hafezi F, Mavrakanas N Corneal Collagen Cross-Linking for Postoperative Corneal Ectasia, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 75–81. 3. Pajic B, Latinovic S, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Fankhauser F Lamellar corneal resection with LDV Crystal line femtosecond laser after penetrating keratoplasty, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 4. Pajic B, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Mueller J, Pajic D, Fankhauser F Applanation-free femtosecond laser processing of the cornea, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 5. Iseli HP, Hafezi F, Mrochen M, Seiler T Estado actual de la reticulación del colágeno corneal, in Técnicas de modelado corneal: desde la ortoqueratologia hasta el cross-linking, Cezón Prieto J, Editor. 2009, Sociedad Española de Cirurgia Ocular Implanto-Refractiva: Madrid. 381–86. 6. Hafezi F, Iseli HP, Seiler T Automated anterior lamellar keratoplasty for the management of complications in refractive surgery, in Surgical techniques in anterior and posterior lamellar corneal surgery, John T, Editor. 2005, Slack Inc.: New York. (in press). 7.
It was expected that uranium would be scarce and high-grade deposits would quickly become depleted if fission power were deployed on a large scale; the reality, however, is that since the end of the Cold War, uranium has been much cheaper and more abundant than early designers expected. Breeder reactors were expected to become economically competitive with light-water reactors. In 2010, Thomas B. Cochran and colleagues reported that demonstration sodium-cooled fast reactors had typically cost more than twice as much per kilowatt of generating capacity as similarly sized water-cooled reactors. They noted that this cost gap might narrow with production, but wrote that few experts anticipated a capital-cost premium below 25%. It was thought that breeder reactors could be as safe and reliable as light-water reactors, but safety issues are cited as a concern with fast reactors that use a sodium coolant, where a leak could lead to a sodium fire. It was expected that the proliferation risks posed by breeders and their "closed" fuel cycle, in which plutonium would be recycled, could be managed. But since plutonium-breeding reactors produce plutonium from U238, and thorium reactors produce fissile U233 from thorium, all breeding cycles could theoretically pose proliferation risks. However U-232, which is always present in U-233 produced in breeder reactors, is a strong gamma-emitter via its daughter products, and would make weapon handling extremely hazardous and the weapon easy to detect.
In 2015, Rachel reunites with Yoshi and they spend the night together catching up and later looking for his missing backpack. When asked about her falling out with Shira, Rachel, while looking a bit guilty, hastily says it was just teen stuff, but that Shira got mad for "no reason". She and Yoshi wind up ending their night in a make out session, which causes Yoshi to ejaculate and ruin his sperm sample for Kendra’s IVF treatment, and when Shira finds out Baby caused him to do so she becomes even more hurt and angry and cements her decision to use an anonymous donor. Danny Burstein as Uncle Barry, Naomi's boisterous, obnoxious uncle by marriage with her aunt Sylvia, the sister of Naomi's mother. Avia Fields as Walter and Benjamin Hooper-Schwooper, the hyperactive twin sons of Kendra and Shira, born in 2015 or 2016. Julie Klausner as Carol Schwartz, one of Naomi's older sisters. Zoe Lister-Jones as Susan Schwartz, one of Naomi's older sisters.
Sources: en.wikipedia.org
== Impact == Martin Müller and Alexander Preker, writing for Der Spiegel in January 2024, have referred to Knudsen discovery in inventing the semaglutide weight-loss injections as "revolutionary", with the "drug Wegovy... [having] changed the world", and having "made Novo Nordisk Europe's most valuable company, with a greater market capitalization than Daimler, Bayer, Lufthansa and BMW combined." In the initial clinical trials for Wegovy, diabetics lost more than 10% of their weight and in trials for weight loss, patients lost an average of 12.4% of their weight. Additional patient benefits included reduction of cardiovascular events by 26%, and benefits to patients with heart and kidney failure. The GLP receptor agonists have reformed treatment outcomes for obesity and diabetes "with profound implications for maintaining human health."
Progesterone is used as a component of feminizing hormone therapy for transgender women in combination with estrogens and often antiandrogens. However, the addition of progestogens to HRT for transgender women is controversial and their role is unclear. Some patients and clinicians believe anecdotally that progesterone may enhance breast development, improve mood, regulate sleep, and increase sex drive. However, there is a lack of evidence from well-designed studies to support these notions at present. In addition, progestogens can produce undesirable side effects, although bioidentical progesterone may be safer and better tolerated than synthetic progestogens like medroxyprogesterone acetate. Because some believe that progestogens are necessary for full breast development, progesterone is sometimes used in transgender women with the intention of enhancing breast development. However, a 2014 review concluded the following on the topic of progesterone for enhancing breast development in transgender women:
=== Influence on other special forces === Following the post-war reconstitution of the Special Air Service, other countries in the Commonwealth recognised their need for similar units. The Canadian Special Air Service Company was formed in 1947, being disbanded in 1949. The New Zealand Special Air Service squadron was formed in June 1955 to serve with the British SAS in Malaya, which became a full regiment in 2011. Australia formed the 1st SAS Company in July 1957, which became a full regiment of the Special Air Service Regiment (SASR) in 1964. On its return from Malaya, the C (Rhodesian) Squadron formed the basis for creation of the Rhodesian Special Air Service in 1961. It retained the name "C Squadron (Rhodesian) Special Air Service" within the Rhodesian Security Forces until 1978, when it became 1 (Rhodesian) Special Air Service Regiment. Non-Commonwealth countries have also formed units based on the SAS. The Belgian Army's Special Forces Group, which wears the same capbadge as the British SAS, traces its ancestry partly from the 5th Special Air Service of the Second World War. The French 1st Marine Infantry Parachute Regiment (1er RPIMa) can trace its origins to the Second World War 3rd and 4th SAS, adopting its "who dares wins" motto. The American unit, 1st Special Forces Operational Detachment-Delta, was formed by Colonel Charles Alvin Beckwith, who served with 22 SAS as an exchange officer, and recognised the need for a similar type of unit in the United States Army.
When the alkali metals react with the heavier elements in the carbon group (silicon, germanium, tin, and lead), ionic substances with cage-like structures are formed, such as the silicides M4Si4 (M = K, Rb, or Cs), which contains M+ and tetrahedral Si4−4 ions. The chemistry of alkali metal germanides, involving the germanide ion Ge4− and other cluster (Zintl) ions such as Ge2−4, Ge4−9, Ge2−9, and [(Ge9)2]6−, is largely analogous to that of the corresponding silicides. Alkali metal stannides are mostly ionic, sometimes with the stannide ion (Sn4−), and sometimes with more complex Zintl ions such as Sn4−9, which appears in tetrapotassium nonastannide (K4Sn9). The monatomic plumbide ion (Pb4−) is unknown, and indeed its formation is predicted to be energetically unfavourable; alkali metal plumbides have complex Zintl ions, such as Pb4−9. These alkali metal germanides, stannides, and plumbides may be produced by reducing germanium, tin, and lead with sodium metal in liquid ammonia.
=== Classical PKU === Classical PKU, and its less severe forms "mild PKU" and "mild hyperphenylalaninemia" are caused by a mutated gene for the enzyme phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine, which is a conditionally essential amino acid for PKU patients, because without the enzyme PAH, tyrosine cannot be produced in the body through oxidation of Phe. PAH deficiency causes a spectrum of disorders, including classic phenylketonuria (PKU) and mild hyperphenylalaninemia (also known as "hyperPhe" or "mild HPA"), a less severe accumulation of phenylalanine. Compared to classic PKU patients, patients with "hyperPhe" have greater PAH enzyme activity and are able to tolerate larger amounts of phenylalanine in their diets. Without dietary intervention, mild HPA patients have blood Phe levels higher than those people with normal PAH activity. Currently, no international consensus exists on the definition of mild HPA, but it is most frequently diagnosed at blood Phe levels between 2 and 6 mg/dL. Phenylalanine is a large, neutral (hydrophobic) amino acid (LNAA). LNAAs compete for transport across the blood–brain barrier (BBB) via the large neutral amino acid transporter (LNAAT). If phenylalanine is in excess in the blood, it saturates the transporter. Excessive phenylalanine levels tend to decrease the levels of other LNAAs in the brain. As these amino acids are necessary for protein and neurotransmitter synthesis, Phe buildup disrupts the development of the brain, causing intellectual disability.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.